Shelf-life estimation of recombinant hepatitis B vaccine using R software in comparison with WHO manual protocol

Authors

  • K Maboudi Pasteur Institute of Iran
  • SB Momen Pasteur Institute of Iran
  • SM Hosseini Pasteur Institute of Iran
  • SN Hoseini Pasteur Institute of Iran
Abstract:

Introduction: Pharmaceutical companies as well as food and cosmetics manufacturers are legally required to provide a shelf-life label on their products packaging as part of their stability study report. There are different recommended software like R software package and SAS which can perform as shelf-life estimating tools for analyzing the data achieved by the stability testing of drugs and vaccines. Methods: Recombinant hepatitis B surface antigen vaccine (Pasteur Institute of Iran) was used as a sample for the entire quality control assays according to Pharmacopeia and NIH (National Institute of Health) procedures. For the stability study, full test examinations were done and R software package was applied to estimate the shelf-life. Results: The results of R software indicated a variety of statistical information which makes the data interpretation more intelligible and apprehensible. Conclusion: Based on our results and experience, the best way to obtain a shelf-life or the expiration date is to calculate it manually however, using software such as R can increase the accuracy of the results.

Upgrade to premium to download articles

Sign up to access the full text

Already have an account?login

similar resources

shelf-life estimation of recombinant hepatitis b vaccine using r software in comparison with who manual protocol

introduction: pharmaceutical companies as well as food and cosmetics manufacturers are legally required to provide a shelf-life label on their products packaging as part of their stability study report. there are different recommended software like r software package and sas which can perform as shelf-life estimating tools for analyzing the data achieved by the stability testing of drugs and va...

full text

Surface protein mutations in chronic hepatitis B patients who received hepatitis B vaccine therapy

Objective (s):The aim of this study was to determine the correlation between vaccine therapy and appearance of mutations in hepatitis B surface antigen (HBsAg)-positive chronic hepatitis B virus (HBV) patients. Materials and Methods: 16 patients received the HBV vaccine and another 16 individuals from the control group did not. The surface gene was amplified and directly sequenced from samples...

full text

Unresponsiveness to Recombinant Hepatitis B Vaccine in Healthy Iranian Neonates: Association with HLA Antigens

Background: Hepatitis B is an important infectious disease.  Since several years ago, mass vaccination against this viral infection has become as part of routine vaccination schedule of Iran.  However, some healthy neonates, children and adults fail to generate a protective antibody response after vaccination.Objectives: To investigate distribution of HLA class-I and class-II antigens in health...

full text

Comparison of the Adjuvanticity of Aluminum Salts and Their Combination in Hepatitis B Recombinant Protein Vaccine Assessed in Mice

Background: Several adjuvants have been evaluated for vaccine formulations but alu-minum salts will continue to be used for many years due to their safety, low cost and adjuvanticity with different antigens. Two commonly used aluminum adjuvants, alumi-num hydroxide and aluminum phosphate have different adjuvanticity properties. Com-mercial recombinant protein hepatitis B vaccines containing alu...

full text

STUDY ON THE EF FICACY OF RECOMBINANT HEPATITIS B VACCINE IN IRANIAN INFANTS

In order to determine the efficacy of recombinant hepatitis B vaccine in Iranian infants, we analyzed the efficacy of a recombinant hepatitis B vaccine in 115 infants aged 12-24 months born to HBsAg negative mothers who received three doses of HBV Antibody to hepatitis B surface antigen (anti-HBs) was checked after the third dose of the vaccine, 94.8% of the infants had developed protective...

full text

Downregulation of IL-12 Production in Healthy Non-Responder Neonates to Recombinant Hepatitis B Vaccine

A proportion of healthy neonates and adults fail to develop a protective antibody response to recombinant hepatitis B (HB) vaccine. Unresponsiveness to vaccination could be attributed to defect in a number of immunological regulatory mechanisms. In this study, IL-12 was quantitated in culture supernatant following in vitro stimulation of peripheral blood mononuclear cells isolated from a group ...

full text

My Resources

Save resource for easier access later

Save to my library Already added to my library

{@ msg_add @}


Journal title

volume 2  issue 1

pages  29- 32

publication date 2015-05

By following a journal you will be notified via email when a new issue of this journal is published.

Keywords

Hosted on Doprax cloud platform doprax.com

copyright © 2015-2023